Melanoma Lymph Node Cytometry Data for Prognostic Biomarker Discovery

29 patients with stage III melanoma provided regional lymph node samples analyzed via mass cytometry (CyTOF) to determine cellular composition. The dataset, authored by Ieva Ailte and last updated in May 2026, includes associated NanoString bulk gene expression data from 125 untreated patients. Findings link specific immune cell populations to distant metastasis-free survival following adjuvant anti-PD-1 therapy.

Use Cases

• Identify prognostic biomarkers for immunotherapy based on immune cell proportions mentioned in the description.
• Validate CyTOF-derived cellular signatures in an independent gene expression cohort as described.
• Model associations between T cell and B cell subsets and clinical outcomes like distant metastasis-free survival.
• Investigate the 'B cell excluded' tumor microenvironment subgroup defined in the untreated patient data.

Strengths

• Includes data from two distinct cohorts: a 29-patient CyTOF cohort and a 125-patient NanoString gene expression cohort.
• Focuses on a clinically relevant population: stage III melanoma patients receiving adjuvant anti-PD-1 therapy.
• Analysis links specific, named cell populations (CD103+PD-1+CD8+ T cells, CD38hiCD19dim cells) to improved prognosis.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The primary data file is a 1.2 MB PDF, which may require extraction of underlying data tables.

Provenance

Source

figshare

Collection Method

Mass cytometry (CyTOF) on surgical lymph node specimens and NanoString gene expression analysis.

Time Range

null

Freshness

Last updated 2026-05-04 04:18:50; freshness should be verified.

Geography

null